نتایج جستجو برای: ipilimumab
تعداد نتایج: 1961 فیلتر نتایج به سال:
PURPOSE Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to as...
Ipilimumab, an anticytotoxic T-lymphocyte–associated protein (CTLA)-4 antibody, was approved in 2011 by the FDA for the treatment of advanced melanoma (1, 2). Our study aimed to evaluate the impact of immunosuppressants used for the treatment of immune-related adverse events (irAE) on outcome of patients treated with ipilimumab. We retrospectively evaluated 113 patients with advanced melanoma a...
Immunomodulation with the anti-CTLA-4 monoclonal antibody ipilimumab has been shown to extend overall survival (OS) in previously treated and treatment-naive patients with unresectable stage III or IV melanoma. Blockade of CTLA-4 signaling with ipilimumab prolongs T-cell activation and restores T-cell proliferation, thus amplifying T-cell-mediated immunity and the patient's capacity to mount an...
Cytotoxic T-lymphocyte-associated antigen is a naturally occurring inhibitor of T-cell costimulation. Monoclonal antibody inhibition of cytotoxic T-lymphocyte-associated antigen with ipilimumab blocks this negative regulator of costimulation, promoting T-cell activation and survival, and leads to melanoma regression. Findings of the Vogt-Koyanagi-Harada (VKH) syndrome, an uveomeningitic syndrom...
BCC: basal cell carcinoma CTLA4: cytotoxic T-lymphocyteeassociated 4 MRI: magnetic resonance imaging INTRODUCTION Ipilimumab, an immune checkpoint inhibitor, is approved for the treatment of advanced melanoma. Its potential activity in keratinocytic cancers, however, is not well known. We present a case of a man in his 60s with advanced basal cell carcinoma (BCC) that regressed after incidental...
Objectives The primary objective is to assess the safely of combining Ipilimumab with palliative radiation therapy in patients with unresectable Stage IV melanoma. Secondary objectives include assessment of 1) induction of anti-melanoma immune responses using laboratory correlative studies of immune responses to melanoma antigens, 2) comparison of tumor response rates and duration of response a...
Introduction Immunotherapy with ipilimumab, a monoclonal antibody anti-Cytotoxic T-Lymphocyte Antigen 4, demonstrated a survival advantage for metastatic melanoma patients, but the treatment is associated with immuno-related adverse events (irAEs) that may drive to severe comorbidities and challenge the treatment prosecution. No predictive factors for significant irAE (grade 3-4 according to Co...
PURPOSE To report a case of severe ocular rosacea following ipilimumab plus nivolumab treatment in a patient with metastatic malignant skin melanoma. METHODS Case report and review of the literature. RESULTS A 68-year-old male with newly diagnosed metastatic malignant cutaneous melanoma was treated with first-line ipilimumab plus nivolumab, which resulted in a partial response. Four months ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید